Lophius Biosciences announced today that the USTPO has granted the U.S. Patent US 78293318 entitled "Use of urea-adjuvanted polypeptides for diagnosis, prophylaxis and therapy".
This patent represents a key building block with respect to Lophius Biosciences T-cell based proprietary UREA technology platform, which has been used by the company already for the development of its diagnostic T-Track® Tx test. This test allows the broad and highly sensitive monitoring of cell-mediated immunity (CMI) in immunosuppressed transplant patients. A corresponding patent has been granted in the E.U already and is nationalized in major markets.
"Following the positive decision by the U.S patent office in early 2010 with respect to patent granting for our proprietary Reverse T-Cell technology, we are very delighted to possess broad patent protection for the UREA technology platform in the most important markets worldwide", said Dr. Michael Lutz, CEO of Lophius Biosciences.
„The UREA technology is a novel platform which enables parallel stimulation of a broad spectrum of clinically relevant immune cells based on its unique mechanism of action. For the 1st time, this allows the development of in vitro diagnostic products that are capable to mimic and evaluate the critical in vivo cellular immune functions. Furthermore, this technology also potentially opens up the opportunity to develop novel adjuvant-free vaccines with a strongly improved profile", added PD Dr. Deml, Chief Scientific Officer of Lophius Biosciences.
Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy